Ocular Surface Findings in Hallopeau-Siemens Subtype of Dystrophic Epidermolysis Bullosa: Report of a Case and Literature Review

Purpose: This article describes the clinical features and long-term changes in corneal sensitivity, tear function, and impression cytology findings in a patient with recessive dystrophic epidermolysis bullosa (DEB). Methods: The patient underwent best-corrected Landolt visual acuity measurements, slit-lamp examinations, anterior segment photography, Schirmer test with anesthesia, tear film break-up time, corneal fluorescein and Rose-Bengal staining, assessment of corneal sensitivity, and conjunctival impression cytology at the initial and final visits. Results: The patient had a recurrent corneal erosion in the right eye and a painful corneal blister with extensive superficial punctuate keratopathy in the left eye, which remained refractory to treatment with patching, lubricants, and antibiotic ointments for 10 weeks. The corneal disease in both eyes responded swiftly to topical fibronectin, topical nonpreserved tears, vitamin A ointment, and therapeutic soft contact lenses. Maintenance treatment was continued with preservative-free topical tear drops and vitamin A ointment. Corneal disease did not recur in the patient during the follow-up of 29 months. The mean corneal sensitivity and tear film break-up time were decreased initially in both eyes and attained normal values with treatment. Impression cytology revealed squamous metaplasia, loss of cellular cohesion, and total absence of goblet cells before treatment, all of which were observed to be normalized at the final follow-up. Conclusions: The ocular surface disease in DEB was characterized by low corneal sensitivity, disorder of tear quality, decreased cellular cohesion, squamous metaplasia of the conjunctiva, and goblet cell loss. Close follow-up for ocular complications in DEB is essential and a pathophysiology-oriented approach to the epithelial disease may not only provide rapid healing but might prevent recurrences as well.

[1]  M. Doğru,et al.  Corneal sensitivity and ocular surface changes following preserved amniotic membrane transplantation for nonhealing corneal ulcers , 2003, Eye.

[2]  P. Khavari,et al.  Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. , 2003, The Journal of clinical investigation.

[3]  C. Creuzot-Garcher,et al.  Treatment of Persistent Corneal Epithelial Defects by Autologous Serum , 2002 .

[4]  M. Barcová,et al.  Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa , 2002, Nature Genetics.

[5]  N. Zoppi,et al.  Different phenotypes in recessive dystrophic epidermolysis bullosa patients sharing the same mutation in compound heterozygosity with two novel mutations in the type VII collagen gene , 2002, The British journal of dermatology.

[6]  H. Horn,et al.  The clinical spectrum of dystrophic epidermolysis bullosa , 2002, The British journal of dermatology.

[7]  Mei Chen,et al.  The Recombinant Expression of Full-length Type VII Collagen and Characterization of Molecular Mechanisms Underlying Dystrophic Epidermolysis Bullosa* , 2002, The Journal of Biological Chemistry.

[8]  K. Wiss.  Epidermolysis bullosa: Clinical, epidemiologic, and laboratory advances and the findings of the National Epidermolysis Bullosa Registry , 2001 .

[9]  J. C. Gómez,et al.  Clinical application of amniotic membranes on a patient with epidermolysis bullosa. , 1999, Annals of transplantation.

[10]  K. Tsubota,et al.  Treatment of persistent corneal epithelial defect by autologous serum application. , 1999, Ophthalmology.

[11]  K. Minakuchi,et al.  Establishment of a standardized assay system of fibronectin activity using fibronectin-mediated cell adhesion. , 1997, Biological & pharmaceutical bulletin.

[12]  T. Chikama,et al.  Fibronectin facilitates corneal epithelial wound healing in diabetic rats. , 1997, Experimental eye research.

[13]  D. Char,et al.  Ocular surface keratinization as a predictor of response to topical retinoic acid therapy. , 1989, Archives of ophthalmology.

[14]  P. McDonnell,et al.  The Ocular Signs and Complications of Epidermolysis Bullosa , 1988, Journal of the Royal Society of Medicine.

[15]  R. E. Smith,et al.  Topical retinoid therapy for squamous metaplasia of various ocular surface disorders. A multicenter, placebo-controlled double-masked study. , 1988, Ophthalmology.

[16]  L. A. Gans,et al.  Eye lesions of epidermolysis bullosa. Clinical features, management, and prognosis. , 1988, Archives of dermatology.

[17]  J. D. Nelson.  Impression Cytology , 1988, Cornea.

[18]  F. Brightbill,et al.  Recessive dystrophic epidermolysis bullosa. , 1987, Archives of ophthalmology.

[19]  S. Tseng,et al.  Topical retinoid treatment for various dry-eye disorders. , 1985, Ophthalmology.

[20]  T. Nishida,et al.  Clinical evaluation of fibronectin eyedrops on epithelial disorders after herpetic keratitis. , 1985, Ophthalmology.

[21]  T. Awata,et al.  FIBRONECTIN EYEDROPS FOR TRAUMATIC RECURRENT CORNEAL EROSION , 1983, The Lancet.

[22]  T. Awata,et al.  Fibronectin. A new therapy for corneal trophic ulcer. , 1983, Archives of ophthalmology.

[23]  M. B. Sulzberger,et al.  Essential Shrinkage of the Conjunctiva in a Case of Probable Epidermolysis Bullosa Dystrophica. , 1935, Transactions of the American Ophthalmological Society.

[24]  A. Sorsby,et al.  Essential shrinking of the conjunctiva in a hereditary affection allied to epidermolysis bullosa , 2004, Documenta Ophthalmologica.

[25]  K. Tsubota,et al.  Effect of retinol palmitate as a treatment for dry eye: a cytological evaluation. , 1997, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.

[26]  P. McDonnell,et al.  The eye in dystrophic epidermolysis bullosa: Clinical and immunopathological findings , 1989, Eye.

[27]  A. Safran,et al.  Corneal hypoesthesia. , 1988, Survey of ophthalmology.

[28]  F. Melton.  Epidermolysis bullosa. , 1955, A.M.A. archives of dermatology.